Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26643283 | 0.95 | MEN1 (0.38) | CYP2C9MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL26643252 | 0.87 | CYP2C9 (0.35) | CYP2C9MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL24600445 | 0.84 | PDE4A (0.32) | MEN1KMT2ARXFP1 | |
| SCHEMBL26643453 | 0.82 | ALDH1A1 (0.36) | CYP2C9MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL29774491 | 0.81 | RXFP1 (0.33) | CYP2C9ALDH1A1MAPTRXFP1 | |
| SCHEMBL29066215 | 0.80 | ALDH1A1 (0.36) | CYP2C9MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL24600252 | 0.79 | CREBBP (0.32) | MEN1KMT2A | |
| SCHEMBL26643524 | 0.77 | PDE7A (0.37) | CYP2C9MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL29527017 | 0.77 | MEN1 (0.39) | CYP2C9MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL24600438 | 0.70 | THRB (0.52) | CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109863-A1 | 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | KPC PHARMACEUTICALS, INC (CN) | 2024-04-04 | — | — | US | disclosed |
| EP-4273139-A1 | 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | KPC Pharmaceuticals, Inc. (CN) | 2023-11-08 | — | — | EP | disclosed |
| WO-2022143574-A1 | 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | 昆药集团股份有限公司 | 2022-07-07 | — | — | WO | disclosed |
| CN-114685450-A | 2-pyridone derivative, preparation method and medical application thereof | 昆药集团股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109863-A1 | 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | PTH1R, MC2R, TSHR | CYP2C9 1082/4885MEN1 254/4885KMT2A 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.